---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026987"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:12:15.709354+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track

## Summary
- Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.
- Cash $148.2M; secured $50M term loan from Hercules Capital, $28.1M drawn.
- COMP360 Phase 3 TRD trials on track; topline data expected summer 2024 (COMP 005) and mid-2025 (COMP 006).
- AMA accepted CPT III code for in-person psychedelic therapy support, aligning with COMP360 requirements.
- ATAI exercised demand registration rights for 7,935,663 shares; filing required within 45 days.

## SEC filing metadata
- accession: 0001628280-23-026987
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/cmps-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026987
- JSON: https://secwatch.observer/filing/0001628280-23-026987.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026987.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported six months ended June 30, 2023 results: net income $52.5 million, or $1.19 loss per share, EPS $1.19 loss per share. Guidance reaffirmed.
  - Period: six months ended June 30, 2023
  - Net income: $52.5 million, or $1.19 loss per share
  - EPS: $1.19 loss per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net loss for the six months ended 30 June 2023 was $52.5 million, or $1.19 loss per share (including non-cash share-based compensation expense of $8.6 million)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm
- Earnings Releases
  COMPASS Pathways plc reported second quarter 2023 results: net income $28.3 million, or $0.62 loss per share, EPS $0.62 loss per share. Guidance reaffirmed.
  - Period: second quarter 2023
  - Net income: $28.3 million, or $0.62 loss per share
  - EPS: $0.62 loss per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net loss for the three months ended 30 June 2023 was $28.3 million, or $0.62 loss per share (including non-cash share-based compensation expense of $4.6 million)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.